Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: CV-787, Calydon Inc.

C Doehn1, D Jocham

  • 1Department of Urology, Medical University of Luebeck, Ratzeburger Allee 160, 23538 Luebeck, Germany. doehn@medinf.mu-luebeck.de

Current Opinion in Molecular Therapeutics
|May 8, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Renal cell carcinoma].

Urologie (Heidelberg, Germany)·2024
Same author

[German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer].

Urologie (Heidelberg, Germany)·2024
Same author

[Update of the German S3 guideline on renal cell carcinoma].

Urologie (Heidelberg, Germany)·2024
Same author

Der Urologe. Ausg. A·2021
Same author

[Immunotherapy and tyrosine kinase inhibitors in first-line treatment of metastatic renal cell carcinoma-Which strategy when?]

Der Urologe. Ausg. A·2020
Same author

[Algorithms for systemic therapy of prostate cancer, transitional cell carcinoma and renal cell carcinoma].

Der Urologe. Ausg. A·2020
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

CV-787, an oncolytic virus therapy, targets prostate cancer by replicating exclusively in prostate-specific antigen (PSA)-producing cells. Clinical trials are evaluating its safety and efficacy in treating both localized and metastatic prostate cancer.

Area of Science:

  • Oncology
  • Virology
  • Gene Therapy

Background:

  • Prostate cancer remains a significant health concern, necessitating novel therapeutic strategies.
  • Current treatments for advanced prostate cancer have limitations, driving the search for innovative approaches.
  • CV-787 is an engineered adenovirus designed for targeted cancer therapy.

Purpose of the Study:

  • To evaluate the safety and tolerability of CV-787 in patients with prostate cancer.
  • To assess the efficacy of CV-787 in reducing prostate-specific antigen (PSA) levels.
  • To determine the optimal dosage for CV-787 administration in phase I/II trials.

Main Methods:

  • CV-787, an attenuated replication-competent adenovirus (ARCA), engineered with a prostate-specific enhancer (PSE).

Related Experiment Videos

  • Phase I/II multi-center, open-label, dose-finding studies in patients with biopsy-proven, prostate-confined, and metastatic prostate cancer.
  • Intravenous administration of CV-787 was investigated in a trial for metastatic disease.

    • Main Results:

    • Enrollment for the intravenous formulation trial was ongoing in April 2001, with a planned enrollment of 48 patients.
    • The study is being conducted across three major medical centers, indicating collaborative research efforts.
    • Primary objectives focus on safety, tolerability, and PSA efficacy, crucial metrics for oncolytic virus therapy.

    Conclusions:

    • CV-787 represents a targeted gene therapy approach for prostate cancer, leveraging viral replication in PSA-producing cells.
    • Early-phase clinical trials are underway to establish the safety and potential efficacy of this novel oncolytic virus.
    • Further research and clinical evaluation are essential to determine the therapeutic role of CV-787 in prostate cancer management.